Program
sonesitatug vedotin
Also written as “AZD0901”, “Sonesitatug Vedotin” and “Sonesitatug vedotin”.
Its studies are mostly in Stomach Neoplasms · Pancreatic Neoplasms, led by 2 companies.
Drug pageSonesitatug vedotin: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 66 open or running | phase 3since Feb 28, 2024 | Dec 7, 2022 | Nov 9, 2027phase 2 · NCT07069712 |
| Keymed Biosciences | 10 open or running | phase 1since Mar 16, 2021 | Mar 16, 2021 | none ahead |
- Named in AstraZeneca’s own pipeline as
sonesitatug vedotin
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Parexel.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseAstraZeneca licensed it from KYM Biosciences (Keymed and Lepu), for worldwide rights.Announced Feb 23, 2023 · Source: AstraZeneca, Feb 23, 2023
History and studies of Keymed Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Mar 16, 2021First study: phase 1 study in Pancreatic NeoplasmsFirst studyNCT04805307 · 176 enrolled · China
- Feb 23, 2023AstraZeneca licensed it from KYM Biosciences (Keymed and Lepu)LicenseWorldwide rights · announced · AstraZeneca
- Aug 11, 2024Named sonesitatug vedotinINNProposed as its International Nonproprietary Name in WHO's List 131 · before, AZD0901, CMG901
TargetBeta
“An antibody-drug conjugate (ADC) composed of sonesitatug, a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), w…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of sonesitatug, a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), ”NCIt, by rule
Other programs on CLDN18
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zolbetuximabrule | Astellas Pharma | phase 4 | 12 |
| garetatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 7 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 6 |
| tecotabart vedotin | Sino Biopharmaceutical | phase 3 | 6 |
| arcotatug tavatecanrule | Innovent Biologics | phase 3 | 5 |
| terallethrinrule | FutureGen Biopharmaceutical (Beijing) | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1 | biokin-shanghai-biopharmaceutical-co-ltd | phase 3 | 3 |
| emaretamigrule | Astellas Pharma | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200rule | Sichuan Kelun Pharmaceutical | phase 2 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Crule | Astellas Pharma | phase 2 | 2 |
| givastomigrule | i-mab-biopharma-us-limited | phase 2 | 2 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863 | AstraZeneca | phase 2 | 1 |
Studies
The one study Keymed Biosciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04805307Pancreatic Neoplasms · China | 1 | Completed | Apr 5, 2024 | 176 |
How it is read
Names in the registry
- “AZD0901”, 5 entries
- “Sonesitatug Vedotin”, 1 entry
- “Sonesitatug vedotin”, 1 entry
- “CMG901”, 1 entry
Conditions, from the studies’ own filings
- Stomach Neoplasms, 6 studies
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.